Ron Axelrod

Ron Axelrod is the Chief Operating Officer at Minerva.

Mr. Axelrod was member of the Crew team at Boston University and rowed in the Head of the Charles until 2006. After completing his degree in Biomedical Engineering, Mr. Axelrod joined the Jet Engine Division of GE, where he worked for ten years. Mr. Axelrod then started a business of brokering networking and communications equipment. In the days before internet auction sites, Ron traveled the country buying out computer lots at auctions and re-selling on the secondary market. Ron has traveled extensively around the globe, currently having visited 110 countries. In 2005, Ron was diagnosed with Multiple Sclerosis and a related platelet disorder. This was the beginning of Ron’s journey into the frontiers of Regenerative Medicine. He started working with Minerva in 2005 when the Company first discovered that the same growth factor receptor and growth factor that mediate the growth of 75% of all cancers – MUC1* and NME’s – also mediate the growth of all human pluripotent stem cells. Ron has been a patient advocate for cell based therapies for MS and for cancers.

At Minerva, Mr. Axelrod is responsible for corporate development, investor relations, facilities and operations, accounting and finance, IT, and procurement. He has raised over $90M in private equity investment for Minerva, which has preserved shareholder value through a strategy of delaying venture capital and institutional investment until a time just prior to initial public offering.